Last filing: Sep 30, 2026.
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 0 of the 13 calendar months from Oct 2025 to Oct 2026.
- No sale on record before this period.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| ADARx Pharmaceuticals, Inc. (ADRX) | Director | Sep 24, 2026 | Sep 30, 2026 |
| Scribe Therapeutics, Inc. (SCTX) | Director | Jul 23, 2026 | Jul 29, 2026 |
| Keros Therapeutics, Inc. (KROS) | Director | Apr 7, 2020 | Dec 18, 2025 |
| Disc Medicine, Inc. (IRON) | Former Director | Feb 10, 2021 | Oct 6, 2021 |
Also a director at
Scribe Therapeutics, Inc. (SCTX), Keros Therapeutics, Inc. (KROS), Disc Medicine, Inc. (IRON) (no filing in the last 18 months)
Recent filings
The last day with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Sep 28, 2026, ADARx Pharmaceuticals, Inc.: bought 588,235 shares for $10.0M (some held indirectly). 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.